Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway
Lexaria Bioscience (Nasdaq:LEXX) has initiated a groundbreaking rodent biodistribution study to track DehydraTECH-processed semaglutide. The study aims to compare the biodistribution patterns of DehydraTECH-processed semaglutide against conventional Rybelsus®-like formulations.
The research utilizes fluorescently tagged semaglutide (FTS) in Sprague-Dawley rats, examining distribution patterns in key tissues including brain, pancreas, lung, kidney, liver, and heart. The study incorporates two test formulations: one mimicking Rybelsus® without DehydraTECH, and another using Lexaria's patented DehydraTECH process.
The study employs immunofluorescence methodology to detect GLP-1 receptor binding, providing detailed insights into tissue distribution and localization patterns. Results will be used to enhance communications with potential industry partners.
Lexaria Bioscience (Nasdaq:LEXX) ha avviato uno studio innovativo sulla biodistribuzione nei roditori per tracciare il semaglutide trattato con DehydraTECH. Lo studio si propone di confrontare i modelli di biodistribuzione del semaglutide trattato con DehydraTECH rispetto a formulazioni convenzionali simili a Rybelsus®.
La ricerca utilizza semaglutide marcato fluorescentemente (FTS) in ratti Sprague-Dawley, esaminando i modelli di distribuzione in tessuti chiave come il cervello, il pancreas, i polmoni, i reni, il fegato e il cuore. Lo studio comprende due formulazioni di prova: una che imita Rybelsus® senza DehydraTECH e l'altra che utilizza il processo brevettato DehydraTECH di Lexaria.
Lo studio impiega una metodologia di immunofluorescenza per rilevare il legame con i recettori GLP-1, fornendo approfondimenti dettagliati sulla distribuzione e i modelli di localizzazione nei tessuti. I risultati saranno utilizzati per migliorare la comunicazione con potenziali partner industriali.
Lexaria Bioscience (Nasdaq:LEXX) ha iniciado un estudio pionero sobre la biodistribución en roedores para rastrear el semaglutido procesado con DehydraTECH. El estudio tiene como objetivo comparar los patrones de biodistribución del semaglutido procesado con DehydraTECH frente a formulaciones convencionales similares a Rybelsus®.
La investigación utiliza semaglutido marcado fluorescente (FTS) en ratas Sprague-Dawley, examinando los patrones de distribución en tejidos clave que incluyen el cerebro, páncreas, pulmón, riñón, hígado y corazón. El estudio incluye dos formulaciones de prueba: una que imita Rybelsus® sin DehydraTECH y otra que utiliza el proceso patentado DehydraTECH de Lexaria.
El estudio emplea una metodología de inmunofluorescencia para detectar la unión de los receptores GLP-1, proporcionando información detallada sobre la distribución y los patrones de localización en los tejidos. Los resultados se utilizarán para mejorar las comunicaciones con posibles socios industriales.
렉사리아 바이오사이언스 (Nasdaq:LEXX)는 DehydraTECH 처리된 세마글루타이드를 추적하기 위한 획기적인 설치류 생체 분포 연구를 시작했습니다. 이 연구의 목적은 DehydraTECH 처리된 세마글루타이드의 생체 분포 패턴을 기존의 Rybelsus® 유사 제형과 비교하는 것입니다.
이 연구는 Sprague-Dawley 쥐에서 형광으로 표지된 세마글루타이드(FTS)를 사용하여 뇌, 췌장, 폐, 신장, 간 및 심장을 포함한 주요 조직의 분포 패턴을 조사합니다. 연구에는 DehydraTECH 없이 Rybelsus®를 모방한 한 가지 제형과 렉사리아의 특허받은 DehydraTECH 공정을 사용하는 다른 하나의 테스트 제형이 포함됩니다.
이 연구는 GLP-1 수용체 결합을 감지하기 위해 면역형광 방법론을 사용하여 조직 분포 및 위치 패턴에 대한 자세한 통찰력을 제공합니다. 결과는 잠재적인 산업 파트너와의 커뮤니케이션을 향상시키는 데 사용될 것입니다.
Lexaria Bioscience (Nasdaq:LEXX) a lancé une étude révolutionnaire sur la biodistribution chez les rongeurs pour suivre le semaglutide traité avec DehydraTECH. L'étude vise à comparer les modèles de biodistribution du semaglutide traité avec DehydraTECH par rapport aux formulations conventionnelles similaires à Rybelsus®.
La recherche utilise du semaglutide marqué par fluorescence (FTS) chez des rats Sprague-Dawley, en examinant les modèles de distribution dans des tissus clés, notamment le cerveau, le pancréas, les poumons, les reins, le foie et le cœur. L'étude comprend deux formulations de test : l'une imitant Rybelsus® sans DehydraTECH, et l'autre utilisant le processus patenté DehydraTECH de Lexaria.
L'étude utilise une méthodologie d'immunofluorescence pour détecter la liaison au récepteur GLP-1, fournissant des informations détaillées sur la distribution et les schémas de localisation dans les tissus. Les résultats seront utilisés pour améliorer les communications avec des partenaires industriels potentiels.
Lexaria Bioscience (Nasdaq:LEXX) hat eine bahnbrechende Studie zur Biodistribution bei Nagetieren gestartet, um DehydraTECH-behandeltes Semaglutid zu verfolgen. Ziel der Studie ist es, die Biodistributionsmuster von DehydraTECH-behandeltem Semaglutid mit herkömmlichen Rybelsus®-ähnlichen Formulierungen zu vergleichen.
Die Forschung verwendet fluoreszenzmarkiertes Semaglutid (FTS) in Sprague-Dawley-Ratten und untersucht die Verteilungsmuster in wichtigen Geweben, darunter Gehirn, Bauchspeicheldrüse, Lunge, Niere, Leber und Herz. Die Studie umfasst zwei Testformulierungen: eine, die Rybelsus® ohne DehydraTECH imitiert, und eine andere, die den patentierten DehydraTECH-Prozess von Lexaria verwendet.
Die Studie verwendet eine Immunfluoreszenz-Methode, um die Bindung an den GLP-1-Rezeptor nachzuverfolgen, und bietet detaillierte Einblicke in die Gewebedistribution und Lokalisation. Die Ergebnisse werden verwendet, um die Kommunikation mit potenziellen Industriepartnern zu verbessern.
- First-ever study tracking biodistribution of DehydraTECH GLP-1 molecules
- Direct comparison with market-leading Rybelsus® formulation
- Study results could support partnership discussions
- None.
Insights
This groundbreaking biodistribution study marks a critical milestone in Lexaria's development of an enhanced oral GLP-1 delivery system. The research design is particularly sophisticated, employing fluorescent tracking and immunofluorescence methodology to provide detailed insights into two key aspects: the spatial distribution of semaglutide throughout major organs and the drug's receptor binding efficiency.
The study's head-to-head comparison with a Rybelsus-mimicking formulation is strategically significant. If DehydraTECH demonstrates superior biodistribution patterns or enhanced receptor binding, it could potentially address several limitations of current GLP-1 medications, including:
- Improved targeting of specific tissues for enhanced therapeutic effect
- Reduced drug accumulation in non-target organs, potentially minimizing side effects
- More efficient receptor binding, which could lead to lower required doses
The inclusion of brain tissue analysis is particularly noteworthy, as it could reveal DehydraTECH's potential to enhance central nervous system penetration - a significant advantage in the GLP-1 space where brain-targeting properties can affect satiety signaling and weight loss outcomes.
The comprehensive tissue examination across major organs (brain, pancreas, lung, kidney, liver and heart) will provide valuable data for potential pharmaceutical partners. Positive results could position Lexaria as a key player in the rapidly expanding GLP-1 market, potentially leading to licensing opportunities or strategic partnerships with major pharmaceutical companies seeking to develop next-generation oral GLP-1 formulations.
World's First-Ever Study Tracking Biodistribution of DehydraTECH GLP-1 Molecules
KELOWNA, BC / ACCESS Newswire / February 6, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that dosing has begun in its fluorescently tagged DehydraTECH-semaglutide ("FTS") rodent biodistribution study (the "Study").
Distribution of a drug once it enters the body can provide vital clues as to the understanding of that drug's ability to bind with targeted receptor cells, avoid concentration at physical sites that might be prone to fostering adverse side effects, and increase the drug's ultimate efficacy. Lexaria hopes to discover whether the DehydraTECH processing of semaglutide improves its biodistribution in any significant way compared to the conventional orally administered semaglutide formulation practice.
The FTS will be tracked via fluorescent imaging detection to evidence how and where semaglutide distributes and localizes following oral ingestion by Sprague-Dawley rats. Later in the Study, the animals will be euthanized and various key tissues will be examined including the brain, pancreas, lung, kidney, liver and heart. These tissues will be subject to more detailed fluorescent imaging detection exams which should show very specific tissue localization patterns and concentrations.
Two different test articles were manufactured for evaluation:
FTS combined with ingredients in the proportions used within the Rybelsus® orally-administered product sold by Novo Nordisk® today designed to mimic Rybelsus® performance, without DehydraTECH processing.
FTS combined with patented DehydraTECH ingredients and processes to evidence potential biodistribution differences when DehydraTECH is used, compared to the Rybelsus®-mimicking control FTS formulation.
The Study includes use of a certain glucagon-like peptide-1 ("GLP-1") receptor that makes specific antibodies detectable through an immunofluorescence methodology. This will allow the analytical laboratory to confirm the extent of GLP-1 receptor binding of the two FTS formulations in the tissue samples taken from the animals, providing an additional detailed measure of the FTS distribution and localization patterns.
Results from the Study will enhance any future communications between Lexaria and prospective industry partners, and additional information will be released when available.
About Lexaria Bioscience Corp. & DehydraTECH
DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 46 patents granted and many patents pending worldwide. For more information, please visit www.lexariabioscience.com.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
ir@lexariabioscience.com
Phone: 250-765-6424, ext 202
SOURCE: Lexaria Bioscience Corp.
View the original press release on ACCESS Newswire
FAQ
What is the purpose of Lexaria's (LEXX) new biodistribution study?
How is LEXX conducting the DehydraTECH-semaglutide biodistribution study?
What are the two formulations being tested in LEXX's GLP-1 study?
How will LEXX measure GLP-1 receptor binding in the biodistribution study?
